Clinical

Patients in this analysis were treated between 2007 and 2020 and could have received radiotherapy either before or after surgery for soft tissue sarcoma (STS).

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management.

Dr Haumschild continues leading an expert discussion surrounding key strategies and pain points in PNH treatment.

Researchers discovered a causal relationship between air pollutants and increased cardiovascular disease (CVD) risk, highlighting the need for protective measures to mitigate exposure.

The association between residual tumor volume after primary cytoreduction and survival was less consistent in patients with low-grade serous ovarian carcinoma (LGSOC) compared with other histology types, highlighting variability in surgical outcomes across ovarian cancer subtypes.

This scientific review examines the potential of targeting the thyroid receptor β (TRβ) for developing new drugs to treat androgenetic alopecia, with the authors discussing various mechanisms by which TRβ might work and analyze promising drug candidates.

Losartan may help stop the epileptic process in certain patients with hypertension.

A high-risk cohort of beneficiaries with chronic kidney disease (CKD) stage 3 have a profile similar to patients with CKD stages 4 and 5, indicating potential benefit of earlier nephrology intervention.

Early findings from a new preclinical study indicate that dual blockade of aurora-A kinase and PD-L1 signaling can inhibit tumor growth in triple-negative breast cancer (TNBC), treatment for which has historically remained limited.

In the realm of lymphoma and chronic lymphocytic leukemia (CLL), and of the treatments that address them, a global survey of nearly 7000 patients proves there’s a long way to go to eliminate cancer-related fatigue from their lives.

In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.

The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Experts in multiple sclerosis discuss overall patient satisfaction with current disease-modifying therapies for multiple sclerosis, highlighting the need for more therapies that stave off decline and disease progression.

Key opinion leaders discuss the most significant unmet needs in the current treatment landscape for multiple sclerosis.

Key opinion leaders provide a concise overview of the atopic dermatitis (AD) treatment landscape, focusing on the role of topical therapy, and highlight the current unmet needs in AD management.

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, address the critical clinical challenges in treating atopic dermatitis (AD) patients and discuss current trends in biologics use for AD.

Researchers have identified a link between psoriasis and the autoimmune diseases hypothyroidism and alopecia areata.

Experts share their biggest takeaways from the European Hematology Association (EHA) 2024 Congress.

Enthusiasm abounded at the recent European Hematology Association 2024 Congress about whether European regulators will begin to consider minimal residual disease (MRD) as an end point.

Atopic dermatitis significantly impairs female patients' sexual function, reproductive desires, and overall quality of life.

The phase 3 GENEr8-1 study demonstrated that valoctocogene roxaparvovec, an AAV5-vectored gene therapy, effectively enabled endogenous FVIII production in adults with severe hemophilia A without developing clinically meaningful FVIII inhibitors.

Patients with stage IV epithelial ovarian cancer (OC) treated with surgery and chemotherapy exhibit the best prognosis.

People receiving hypomethylating agent (HMA) therapy spent 33 more days at home than people receiving anthracycline-based therapy in the first year after diagnosis.

Pfizer’s investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, did not meet its primary end point of improvement in motor function in ambulatory patients with Duchenne muscular dystrophy (DMD).

Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.

Dr Haumschild continues leading a discussion surrounding management of PNH, emphasizing the impact of complement inhibitors.

Determining the roles that various inflammatory markers and pathways play in lower-risk myelodysplastic syndromes (MDS) could lead to therapies that keep disease progression at bay.

This study provides a comprehensive review of both established and emerging prognostic markers in chronic lymphocytic leukemia (CLL), and their role in predicting disease, treatment response, and overall survival.

Study findings show eculizumab is effective and well tolerated in reducing disease burden in adolescents with refractory anti-acetylcholine receptor antibody–positive generalized myasthenia gravis.

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) in the phase 3 FLAURA2 study.